Followed by ChongKunDang 481.3BㆍPfizer 437.9B
38 companies exceed 100B...Celltrion’s growth rate is highest at 51.88%
<KOREA>Hanmi Pharmaceutical is expected to reach the 600 billion won mark for the first time in the outpatient prescription market.
According to UBIST, Hanmi Pharm recorded cumulative prescriptions of 556.3 billon won until last November, exceeding the annual prescription record of 551.6 billon won in 2018.
The year on year growth rate was 11.59%, the only double dight rate among the top five outpatient prescription market players.
Hanmi is also the only company among the top five companies that has surpassed the annual prescriptions in 2018 based on the cumulative prescriptions during November.
In particular, the company has maintained more than 50 billion monthly prescriptions for six consecutive months since July 2018 and if this trend continued until December, it will likely surpass 600 billion won. Cumulative prescriptions through December will be announced around the middle of this month.
ChongKunDang, which narrowly failed to reach the 500 billion won mark on 496 billion won in 2018, is expected to achieve the 500 billon won mark without difficulty.
The Cumulative prescriptions alone in the first 11 months of last year posted 481.3 billion won, recording more than 40 billion in monthly prescriptions, which is certain to reach the 500 billion won mark.
Following ChongKunDang, Pfizer grew 7.80% to 437.9 billion won, reaching close to the 450 billion won mark that could not achieved in 2018.
Daewoong Pharm, which followed suit, grew just 3.18% to 376.4 billion won in prescriptions for 11 months and is expected to record early 400 billion won in prescriptions in 2019 following 2018.
MSD is not expected to achieve the 400 billion won mark in cumulative prescriptions. The cumulative prescriptions was 363.8 billion won in 11 months, increased only 4.72% year on year.
The maximum monthly prescriptions recorded in last October was 35.8 billion won, which can be reach the 400 billlion won mark only if it exceeds 1 billion won in December.
AstraZeneca rose to 299.6 billion won by recording a growth rate of 10.89%, the second highest growth rate among the top 10 outpatient prescriptions market player, surpassing its annual prescriptions in 2018 within 11 months.
Boehringer Ingelheim also recorded prescriptions of 290.8 billlion won with a growth rate of 9.81%, and is near the 300 billion won mark above the annual prescriptions in 2018.
On the other hand, Novartis, whose prescriptions has been decreasing recently, grew only 0.83% over 11 months at 281.9 billion won. However, it seems that there will be no difficulty in reaching the 300 billion won mark.
CJ HealthCare continued to grow 9.18%, but the 11 months cumulative prescriptions was 260.9 billion won, far from the 300 billion won mark.
Next, Yuhan Corporation grew 7.41% to 245.6 billlion won in prescriptions reaching close to the 250 billion won mark, Handok also showed the possibility of achieving the 250 billion won mark, rising to 236.9 billion won with a growth rate of 7.09%.
In addition, Daewon Pharm increased prescriptions by 7.40% to 222.1 billlion won, Dong-A ST grew 1.50% to 217.1 billion won, exceeding 200 billion won in 11 months, but it is unlikely to exceed 250 billlion won.
Daewoong Bio, which recorded prescriptions of 173.8 billion won in 2018, achieved 195.5 billion won in first 11 months of last year, up 24.19%, with close to the 200 billion won mark.
Astellas Pharma also recorded 184.5 billion won in prescriptions in the first 11 months of last year, up from 179.5 billion won in 2018, opening up the possibility of reaching the 200 billion mark.
On the other hand, Samjin Pharmaceuticals, which recorded prescriptions of 211.1 billion won in 2018, fell by 7.83% to 178.2 billion, making it difficult to reach the 200 billion mark. JW Pharmaceutical also recorded 170.8 billion won in degrowth of 2.54%, far from the 200 billion mark.
Meanwhile, Korea United Pharm posted 167.2 billion won in prescriptions with growth rate of 10.27%, surpassing the annual prescriptions in 2018.
Jeil Pharmaceutical also grew 18.10% to 164.7 billion won, surpassing the annual prescriptions in 2018, while GSK also grew 5.39% to 158.2 billion won, once again reaching to the 150 billion won mark.
Ildong Pharmaceutical degrew 0.06% year on year to 156.2 billion won over the same period. Hutecs grew 9.27% to 156.1 billion won, reaching the 150 billion won mark a month earlier than 2018.
Hanlim Pharm also posted 155.8 billion won in prescriptions at 6.59% growth, surpassing the 150 billion mark a month earlier.
LG Chem which recorded prescriptions of 129.1 billion won in 2018, grew 28.90% reaching the 150 billion won mark within 11 months.
Celltrion managed to reach the 100 billion won mark in 2018, but it achieved 148.8 billion won in prescriptions in 11 months of last year, hoping to reach the 150 billion mark.
The growth rate recorded during this period was 51.88%, the highest among the companies that recorded over 100 billion won in prescriptions in the first 11 months of last year.
Following Celltrion, Boryung Pharmaceutical also achieved 144.3 billion won in prescriptions, up 13.27% over 11 months, close to the 150 billion won mark that it had not exceeded in 2018.
Daiichi Sankyo reached the 130 billion won with a growth rate of over 20%(129.5 billion won), and SK Chemicals, Bayer, Hana Pharm, MyungMoon Pharm, Gilead, Huons, Ahn-gook Pharm, BMS, Bukwang Pharm exceeded the 100 billion mark.
A total of 38 companies recorded more than 100 billion won in prescriptions by November last year, all of which exceeded 100 billion in 2018.
Among other companies, Aju Pharm, Korea Kolmar, and Janssen recorded cumulative prescriptions of late 800 billion won each, that are the closest to the 100 billion won mark in 11 months.
However, it is unlikely to reach the 100 billion mark given the average monthly prescriptions remains at about 8 billion won. As a result, the number of 100 billion companies is expected to remain at the level of 2018.
With no new companies rising to the 100 billion mark or retreating from 100 billion mark by November last year, the list of 100 billion companies is expected to be the same as in 2018.